Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

Bonneterre, J.; U. Buzdar, Aman; Nabholtz, Jean‐Marc; F. R. Robertson, John; Th�rlimann, Bert; von Euler, Mikael; Sahmoud, Tarek; Webster, Alan; L. Steinberg, Mark

doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y

Public

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

Published in Cancer • Jan 1, 2001

Authors:

J. Bonneterre

Aman U. Buzdar

Jean‐Marc Nabholtz

Abstract

BACKGROUND: Two randomized, double-blind trials have compared tamoxifen 20 mg daily and the selective, nonsteroidal aromatase inhibitor anastrozole 1 mg daily as first-line therapy for advanced breast carcinoma (ABC) in postmenopausal women. The trials were prospectively designed to allow for combin...

Subject

Anastrozole

Medicine

Tamoxifen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!